Dendreon Appoints Linda Staley as Vice President, Information Technology.

SEATTLE -- Dendreon Corporation (Nasdaq:DNDN) today announced that Linda Staley has been appointed vice president, information technology. Staley will be responsible for overseeing strategic planning and technology assessment to guide the implementation of information technology infrastructure necessary to support the commercialization of Provenge(R), Dendreon's therapeutic cancer vaccine currently in phase 3 clinical trials for prostate cancer, and other products.

Staley spent the last 13 years at Cardinal Health, Inc.'s Nuclear Pharmacy Division where she was most recently executive director, pharmacy services liaison, information technologies. At Cardinal Health, Staley directed a staff of 143 and was responsible for developing and implementing a global strategy for reorganizing the information technology infrastructure, reducing overall expenses by 21 percent.

"Linda's extensive experience in supporting a high-growth organization and in-depth knowledge of corporate-wide systems will make information systems a sustainable, competitive advantage for Dendreon as we pursue our commercialization plans," said Martin Simonetti, senior vice president, finance and chief financial officer.

Before joining Cardinal Health in 1990, Staley was chief nuclear medicine technologist / radiation safety officer at Montgomery Cardiovascular Associates where she directed the development of a new Nuclear Cardiology Department.

Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge(R), is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial for the treatment of androgen independent prostate cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody, small molecule and pro-drug product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include reliance on directors, officers, and key employees, risks related to Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the results of a clinical trial, including Phase 3 trials of Provenge, will not support applying for or approval of a biologics license by the FDA, the risks associated with development of manufacturing capabilities and other infrastructure to support commercialization, including the risks that we may be unable to successfully scale up our manufacturing and production capabilities or may lack adequate capital to do so, the risk that our product candidates, if approved for sale, may have none or limited commercial success, the risk that clinical trials may be suspended or terminated because of unacceptable health risks or for other reasons, and the risks that our competitors may develop products that are safer, more effective or reach the market sooner than our product candidates, the uncertainty of Dendreon's future access to capital, the risk that Dendreon may not secure or maintain relationships with collaborators, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.